<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586118</url>
  </required_header>
  <id_info>
    <org_study_id>ANA06104</org_study_id>
    <secondary_id>ANA06104</secondary_id>
    <nct_id>NCT00586118</nct_id>
  </id_info>
  <brief_title>Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Ludwigshafen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Ludwigshafen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The evaluation of the presented study will work on the practicability of inhalative sedation&#xD;
      on the ICU, potential benefits and limitations of the ACD system in a postoperative sedated&#xD;
      patient population in comparison to a standard intravenous sedation regimen with propofol,&#xD;
      and focus on renal and hepatic function, cardioprotection and pharmacoeconomics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A goal-oriented sedation complies the ability to sedate the patient as deeply as necessary,&#xD;
      and allow a modern ventilation regimen with early spontaneous breathing and a pain-free&#xD;
      cooperative patient. The ideal sedative agent - with a short duration of action, predictable&#xD;
      wake-up times, low drug toxicity, haemodynamic stability and less side effects, and a&#xD;
      rational pharmacoeconomic impact nowadays - has still to be found. Inhalative anaesthetics&#xD;
      show these properties, but until the introduction of AnaConDa© (Anesthetic Conserving Device,&#xD;
      ACD) in 2005, the use of volatile anaesthetics on the intensive care unit (ICU) required&#xD;
      specific evaporating devices or scavenging systems. The ACD, a modified heat- moisture&#xD;
      filter, is connected to the breathing circuit of conventional ICU ventilators and a syringe&#xD;
      pump delivers the volatile anaesthetic to the ACD where it is vaporized through a rod. Most&#xD;
      of the exhaled gas is absorbed in a charcoal filter's membrane and reflected to the patient&#xD;
      in the following inspiration. Randomised, controlled and comparative studies to the use of&#xD;
      volatile anaesthetics in ICU via this innovative device are still missing. Isoflurane has&#xD;
      been studied in small patient populations and in comparison to midazolam, while Sevoflurane -&#xD;
      a newer volatile agent with short action, brief elimination time, and low hepatic&#xD;
      biodegradation - has only been studied intraoperatively and in short-term sedation. This is&#xD;
      the first prospective, randomised, clinical study on the feasibility of sevoflurane via the&#xD;
      ACD for sedation in ICU patients until 72 hours in comparison to a standard intravenous&#xD;
      sedation with propofol. The investigation will work on potential benefits and limitations of&#xD;
      the use of volatile agents on the ICU, the quality of sedation (Richmond Agitation Sedation&#xD;
      Scale, BIS), infusion rate stability of sevoflurane and respiratory parameters, short-term&#xD;
      recovery (time from discontinuation of infusion until following verbal commands and&#xD;
      extubation), haemodynamics, renal and hepatic function and adverse side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extubation time</measure>
    <time_frame>Termination of sedation to extubation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consumption of anaesthetics</measure>
    <time_frame>until discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>until discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic function</measure>
    <time_frame>until discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioprotection</measure>
    <time_frame>until discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>until discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Recovery From Sedation</condition>
  <condition>Sevoflurane Consumption</condition>
  <condition>Renal Function</condition>
  <condition>Hepatic Function</condition>
  <condition>Cardioprotection</condition>
  <arm_group>
    <arm_group_label>1-Sevo</arm_group_label>
    <description>Sevoflurane/ACD group (n=60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Propofol</arm_group_label>
    <description>Propofol group (n=60)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU</description>
    <arm_group_label>1-Sevo</arm_group_label>
    <other_name>Sevorane (Abbott GmbH, Wiesbaden, Germany)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours</description>
    <arm_group_label>2-Propofol</arm_group_label>
    <other_name>disoprivan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 patients, scheduled for elective major surgery and postoperative admission to the ICU,&#xD;
        are screened the day before surgery for potential in- and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years&#xD;
&#xD;
          -  elective operative procedure, and indication for admission to the ICU for&#xD;
             postoperative sedation&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  weight 50-120 kg&#xD;
&#xD;
          -  Haemoglobin &gt; 10 g/dl&#xD;
&#xD;
          -  ability and acceptance to agree to the study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  malignant hyperthermia&#xD;
&#xD;
          -  muscle diseases or weakness&#xD;
&#xD;
          -  liver insufficiency (ASAT, ALAT &gt; 40 U/min)&#xD;
&#xD;
          -  pancreas insufficiency&#xD;
&#xD;
          -  emergencies&#xD;
&#xD;
          -  women in child bearing age and missing negative pregnancy test, pregnancy or lactation&#xD;
&#xD;
          -  diseases from the central nervous system (such as M. Parkinson and multiple sclerosis)&#xD;
&#xD;
          -  increased intracranial pressure, head trauma&#xD;
&#xD;
          -  pre-existing delirium, agitation and psychiatric derangements&#xD;
&#xD;
          -  alcohol and drug abuse (including opioid abuse)&#xD;
&#xD;
          -  allergy to any of the study agents&#xD;
&#xD;
          -  refusal from the patient to participate in the study&#xD;
&#xD;
          -  participation in another study project.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin D. Röhm, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Ludwigshafen, Department of Anaesthesiology, Ludwigshafen, Germany</affiliation>
  </overall_official>
  <reference>
    <citation>Sackey PV, Martling CR, Nise G, Radell PJ. Ambient isoflurane pollution and isoflurane consumption during intensive care unit sedation with the Anesthetic Conserving Device. Crit Care Med. 2005 Mar;33(3):585-90.</citation>
    <PMID>15753751</PMID>
  </reference>
  <reference>
    <citation>Sackey PV, Martling CR, Granath F, Radell PJ. Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med. 2004 Nov;32(11):2241-6.</citation>
    <PMID>15640636</PMID>
  </reference>
  <reference>
    <citation>Berton J, Sargentini C, Nguyen JL, Belii A, Beydon L. AnaConDa reflection filter: bench and patient evaluation of safety and volatile anesthetic conservation. Anesth Analg. 2007 Jan;104(1):130-4.</citation>
    <PMID>17179257</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>January 3, 2008</last_update_submitted>
  <last_update_submitted_qc>January 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Klinkum Ludwigshafen, Department of Anaesthesiology and Intensive Care</name_title>
    <organization>Dr. K. D. Röhm, Klinikum Ludwigshafen, Dep. of Anaesthesiology</organization>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Volatile anaesthetic</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Propofol</keyword>
  <keyword>Recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

